

## Summary statistics - qualitative results

(Groups: manufacturer of kit)

## EQA round: IHC1/19 - Immunohistochemistry - Detection of HER-2/neu

Dead line: 29.04.2019

Key:	>>> ... marks correct (expected) result	N ... number of the results
	> ... marks conditionally correct (acceptable) result	Nrel ... relative number of the results
	± ... marks the result not evaluated	

## Test

Sample	Group	N	Result	N <sub>rel</sub>
<b>(601) A1 expression HER-2/neu</b>				
Slide	(802) Dako HercepTest	>>> 7	Negative (0)	16 %
	(803) Dako c-erbB-2 Onkoprotein	>>> 11	Negative (0)	24 %
	(804) Ventana PATHWAY anti-HER-2/neu	>>> 24	Negative (0)	53 %
	(999) another manufacturer	>>> 3	Negative (0)	6,7 %
Total per sample: n = 45		Success: 100 %		
Total success: 100 %				

**(602) A2 expression HER-2/neu**

Slide	(802) Dako HercepTest	> 2	Negative (1)	4,4 %
		>>> 5	Weak positivity	11 %
	(803) Dako c-erbB-2 Onkoprotein	2	Negative (0)	4,4 %
		> 3	Negative (1)	6,7 %
		>>> 6	Weak positivity	13 %
	(804) Ventana PATHWAY anti-HER-2/neu	> 7	Negative (1)	16 %
		>>> 17	Weak positivity	38 %
	(999) another manufacturer	> 3	Negative (1)	6,7 %
Total per sample: n = 45		Success: 96 %		
Total success: 96 %				

**(603) A3 expression HER-2/neu**

Slide	(802) Dako HercepTest	>>> 7	Strong positivity	16 %
	(803) Dako c-erbB-2 Onkoprotein	>>> 11	Strong positivity	24 %
	(804) Ventana PATHWAY anti-HER-2/neu	>>> 24	Strong positivity	53 %
	(999) another manufacturer	>>> 3	Strong positivity	6,7 %
Total per sample: n = 45		Success: 100 %		
Total success: 100 %				

**(606) B1 expression HER-2/neu**

Slide	(802) Dako HercepTest	> 3	Negative (0)	6,7 %
		>>> 4	Negative (1)	8,9 %
	(803) Dako c-erbB-2 Onkoprotein	> 6	Negative (0)	13 %
		>>> 4	Negative (1)	8,9 %
		1	Weak positivity	2,2 %
	(804) Ventana PATHWAY anti-HER-2/neu	> 16	Negative (0)	36 %
		>>> 7	Negative (1)	16 %
		1	Weak positivity	2,2 %
	(999) another manufacturer	> 2	Negative (0)	4,4 %
		>>> 1	Negative (1)	2,2 %
Total per sample: n = 45		Success: 96 %		
Total success: 96 %				

**(607) B2 expression HER-2/neu**

Slide	(802) Dako HercepTest	>>> 7	Strong positivity	16 %
	(803) Dako c-erbB-2 Onkoprotein	>>> 11	Strong positivity	24 %
	(804) Ventana PATHWAY anti-HER-2/neu	>>> 24	Strong positivity	53 %
	(999) another manufacturer	>>> 3	Strong positivity	6,7 %
Total per sample: n = 45		Success: 100 %		
Total success: 100 %				

**(608) B3 expression HER-2/neu**

Slide	(802) Dako HercepTest	> 4	Negative (0)	8,9 %
		>>> 2	Negative (1)	4,4 %
		1	Weak positivity	2,2 %
	(803) Dako c-erbB-2 Onkoprotein	> 6	Negative (0)	13 %
		>>> 4	Negative (1)	8,9 %
		1	Weak positivity	2,2 %
	(804) Ventana PATHWAY anti-HER-2/neu	> 23	Negative (0)	51 %
		>>> 1	Negative (1)	2,2 %
	(999) another manufacturer	> 2	Negative (0)	4,4 %
		>>> 1	Negative (1)	2,2 %
Total per sample: n = 45		Success: 96 %		
Total success: 96 %				

**(611) C1 expression HER-2/neu**

Slide	(802) Dako HercepTest	>>> 7	Weak positivity	16 %
	(803) Dako c-erbB-2 Onkoprotein	>>> 10	Weak positivity	22 %
		> 1	Strong positivity	2,2 %
	(804) Ventana PATHWAY anti-HER-2/neu	> 4	Negative (1)	8,9 %
		>>> 20	Weak positivity	44 %

## Summary statistics - qualitative results

(Groups: manufacturer of kit)

## EQA round: IHC1/19 - Immunohistochemistry - Detection of HER-2/neu

Dead line: 29.04.2019

Test			N	Result	N <sub>rel</sub>
Sample	Group				
Slide	(999) another manufacturer	>	1	Negative (1)	2,2 %
		>>>	2	Weak positivity	4,4 %
Total per sample: n = 45		Success: 100 %			
Total success: 100 %					
<b>(612) C2 expression HER-2/neu</b>					
Slide	(802) Dako HercepTest	>	3	Negative (1)	6,7 %
		>>>	4	Weak positivity	8,9 %
	(803) Dako c-erbB-2 Onkoprotein	>	1	Negative (1)	2,2 %
		>>>	9	Weak positivity	20 %
		>	1	Strong positivity	2,2 %
	(804) Ventana PATHWAY anti-HER-2/neu	>	10	Negative (1)	22 %
		>>>	14	Weak positivity	31 %
	(999) another manufacturer	>	3	Negative (1)	6,7 %
Total per sample: n = 45		Success: 100 %			
Total success: 100 %					
<b>(613) C3 expression HER-2/neu</b>					
Slide	(802) Dako HercepTest	>>>	6	Weak positivity	13 %
		>	1	Strong positivity	2,2 %
	(803) Dako c-erbB-2 Onkoprotein	>>>	10	Weak positivity	22 %
		>	1	Strong positivity	2,2 %
	(804) Ventana PATHWAY anti-HER-2/neu	>	1	Negative (1)	2,2 %
		>>>	23	Weak positivity	51 %
	(999) another manufacturer	>>>	3	Weak positivity	6,7 %
Total per sample: n = 45		Success: 100 %			
Total success: 100 %					
<b>(616) D1 expression HER-2/neu</b>					
Slide	(802) Dako HercepTest		1	Negative (0)	2,2 %
		>	3	Negative (1)	6,7 %
		>>>	3	Weak positivity	6,7 %
	(803) Dako c-erbB-2 Onkoprotein		2	Negative (0)	4,4 %
		>	3	Negative (1)	6,7 %
		>>>	6	Weak positivity	13 %
	(804) Ventana PATHWAY anti-HER-2/neu	>	16	Negative (1)	36 %
		>>>	8	Weak positivity	18 %
	(999) another manufacturer		1	Negative (0)	2,2 %
		>	2	Negative (1)	4,4 %
Total per sample: n = 45		Success: 91 %			
Total success: 91 %					
<b>(617) D2 expression HER-2/neu</b>					
Slide	(802) Dako HercepTest	>	1	Negative (0)	2,2 %
		>>>	5	Negative (1)	11 %
			1	Weak positivity	2,2 %
	(803) Dako c-erbB-2 Onkoprotein	>	3	Negative (0)	6,7 %
		>>>	5	Negative (1)	11 %
			3	Weak positivity	6,7 %
	(804) Ventana PATHWAY anti-HER-2/neu	>	8	Negative (0)	18 %
		>>>	14	Negative (1)	31 %
			2	Weak positivity	4,4 %
	(999) another manufacturer	>	2	Negative (0)	4,4 %
		>>>	1	Negative (1)	2,2 %
Total per sample: n = 45		Success: 87 %			
Total success: 87 %					
<b>(618) D3 expression HER-2/neu</b>					
Slide	(802) Dako HercepTest	>>>	7	Negative (0)	16 %
	(803) Dako c-erbB-2 Onkoprotein	>>>	10	Negative (0)	22 %
		>	1	Negative (1)	2,2 %
	(804) Ventana PATHWAY anti-HER-2/neu	>>>	24	Negative (0)	53 %
	(999) another manufacturer	>>>	3	Negative (0)	6,7 %
Total per sample: n = 45		Success: 100 %			
Total success: 100 %					
<b>(621) E1 expression HER-2/neu</b>					
Slide	(802) Dako HercepTest	>>>	7	Strong positivity	16 %
	(803) Dako c-erbB-2 Onkoprotein	>>>	11	Strong positivity	24 %
	(804) Ventana PATHWAY anti-HER-2/neu	>>>	24	Strong positivity	53 %
	(999) another manufacturer	>>>	3	Strong positivity	6,7 %
Total per sample: n = 45		Success: 100 %			
Total success: 100 %					

## Summary statistics - qualitative results

(Groups: manufacturer of kit)

## EQA round: IHC1/19 - Immunohistochemistry - Detection of HER-2/neu

Dead line: 29.04.2019

## Test

Sample	Group	N	Result	N <sub>rel</sub>
<b>(622) E2 expression HER-2/neu</b>				
Slide	(802) Dako HercepTest	>>>	7 Negative (0)	16 %
	(803) Dako c-erbB-2 Onkoprotein	>>>	11 Negative (0)	24 %
	(804) Ventana PATHWAY anti-HER-2/neu	>>>	23 Negative (0)	51 %
		>	1 Negative (1)	2,2 %
	(999) another manufacturer	>>>	3 Negative (0)	6,7 %
Total per sample: n = 45		Success: 100 %		
Total success: 100 %				

**(623) E3 expression HER-2/neu**

Slide	(802) Dako HercepTest		1 Negative (0)	2,2 %
		>	2 Negative (1)	4,4 %
		>>>	4 Weak positivity	8,9 %
	(803) Dako c-erbB-2 Onkoprotein		2 Negative (0)	4,4 %
		>	3 Negative (1)	6,7 %
		>>>	6 Weak positivity	13 %
	(804) Ventana PATHWAY anti-HER-2/neu		1 Negative (0)	2,2 %
		>	18 Negative (1)	40 %
		>>>	5 Weak positivity	11 %
	(999) another manufacturer		1 Negative (0)	2,2 %
		>	1 Negative (1)	2,2 %
		>>>	1 Weak positivity	2,2 %
Total per sample: n = 45		Success: 89 %		
Total success: 89 %				

**(651) A1 sample staining**

Slide	(0) not specified		>	1 11 points	2,2 %
			>>>	1 14 points	2,2 %
			>>>	43 15 points	96 %
Total per sample: n = 45		Success: 100 %			
Total success: 100 %					

**(652) A2 sample staining**

Slide	(0) not specified		6	0 points	13 %
			1	6 points	2,2 %
			1	7 points	2,2 %
		>	8	9 points	18 %
		>	4	11 points	8,9 %
		>>>	5	13 points	11 %
		>>>	20	15 points	44 %
Total per sample: n = 45		Success: 82 %			
Total success: 82 %					

**(653) A3 sample staining**

Slide	(0) not specified		>>>	2 14 points	4,4 %
			>>>	43 15 points	96 %
Total per sample: n = 45		Success: 100 %			
Total success: 100 %					

**(656) B1 sample staining**

Slide	(0) not specified		1	7 points	2,2 %
		>	1	9 points	2,2 %
		>>>	1	13 points	2,2 %
		>>>	42	15 points	93 %
Total per sample: n = 45		Success: 98 %			
Total success: 98 %					

**(657) B2 sample staining**

Slide	(0) not specified		>	1 12 points	2,2 %
			>>>	1 14 points	2,2 %
			>>>	43 15 points	96 %
Total per sample: n = 45		Success: 100 %			
Total success: 100 %					

**(658) B3 sample staining**

Slide	(0) not specified		>	2 11 points	4,4 %
			>>>	3 13 points	6,7 %
			>>>	3 14 points	6,7 %
			>>>	37 15 points	82 %
Total per sample: n = 45		Success: 100 %			
Total success: 100 %					

**(661) C1 sample staining**

Slide	(0) not specified		1	7 points	2,2 %
		>	13	9 points	29 %
		>	1	11 points	2,2 %

## Summary statistics - qualitative results

(Groups: manufacturer of kit)

## EQA round: IHC1/19 - Immunohistochemistry - Detection of HER-2/neu

Dead line: 29.04.2019

Test			N	Result	N <sub>rel</sub>		
Sample	Group						
Slide	(0) not specified	>	1	12 points	2,2 %		
		>>>	4	13 points	8,9 %		
		>>>	25	15 points	56 %		
		Total per sample: n = 45		Success: 98 %			
Total success: 98 %							
<b>(662) C2 sample staining</b>							
Slide	(0) not specified		4	0 points	8,9 %		
			1	7 points	2,2 %		
		>	14	9 points	31 %		
		>	3	11 points	6,7 %		
		>>>	3	13 points	6,7 %		
		>>>	20	15 points	44 %		
Total per sample: n = 45		Success: 89 %					
Total success: 89 %							
<b>(663) C3 sample staining</b>							
Slide	(0) not specified	>	2	9 points	4,4 %		
		>>>	2	13 points	4,4 %		
		>>>	2	14 points	4,4 %		
		>>>	39	15 points	87 %		
Total per sample: n = 45		Success: 100 %					
Total success: 100 %							
<b>(666) D1 sample staining</b>							
Slide	(0) not specified		8	0 points	18 %		
			1	3 points	2,2 %		
			3	7 points	6,7 %		
		>	16	9 points	36 %		
		>	1	10 points	2,2 %		
		>	2	11 points	4,4 %		
		>>>	14	15 points	31 %		
Total per sample: n = 45		Success: 73 %					
Total success: 73 %							
<b>(667) D2 sample staining</b>							
Slide	(0) not specified	>	5	9 points	11 %		
		>	1	12 points	2,2 %		
		>>>	3	13 points	6,7 %		
		>>>	2	14 points	4,4 %		
		>>>	34	15 points	76 %		
Total per sample: n = 45		Success: 100 %					
Total success: 100 %							
<b>(668) D3 sample staining</b>							
Slide	(0) not specified	>>>	2	13 points	4,4 %		
		>>>	3	14 points	6,7 %		
		>>>	40	15 points	89 %		
Total per sample: n = 45		Success: 100 %					
Total success: 100 %							
<b>(671) E1 sample staining</b>							
Slide	(0) not specified	>	1	12 points	2,2 %		
		>>>	44	15 points	98 %		
Total per sample: n = 45		Success: 100 %					
Total success: 100 %							
<b>(672) E2 sample staining</b>							
Slide	(0) not specified	>	1	8 points	2,2 %		
		>>>	1	13 points	2,2 %		
		>>>	43	15 points	96 %		
Total per sample: n = 45		Success: 100 %					
Total success: 100 %							
<b>(673) E3 sample staining</b>							
Slide	(0) not specified		10	0 points	22 %		
			1	3 points	2,2 %		
			1	6 points	2,2 %		
			3	7 points	6,7 %		
		>	22	9 points	49 %		
		>	1	10 points	2,2 %		
		>	2	11 points	4,4 %		
		>>>	5	15 points	11 %		
		Total per sample: n = 45		Success: 67 %			

**Summary statistics - qualitative results**

(Groups: manufacturer of kit)

**EQA round: IHC1/19 - Immunohistochemistry - Detection of HER-2/neu**

Dead line: 29.04.2019

**Test**

Sample	Group	N	Result	N <sub>rel</sub>
Total success: 67 %				

**(681) IQC**

Slide	(0) not specified	3	0 points	6,7 %
		1	1 point	2,2 %
		1	2 points	2,2 %
		7	3 points	16 %
		2	4 points	4,4 %
	>	2	5 points	4,4 %
	>	9	6 points	20 %
	>	1	7 points	2,2 %
	>>>	7	8 points	16 %
	>>>	12	9 points	27 %

----- Total per sample: n = 45 ----- Success: 69 % -----

Total success: 69 %

st\_kl

End of report

Printed: 29.05.2019